GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Disopyramide

Read renal action and limits

Norpace / Norpace CR / Disopyramide phosphate

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Norpace / Norpace CR - product and source limitations

Confirm the release formulation before selecting an interval and monitor conduction and anticholinergic toxicity.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Norpace / Norpace CR - product and source limitations

Rxlist source

Norpace / Norpace CR - selected RX renal passage

Product / population
Disopyramide phosphate (Norpace / Norpace CR), oral capsules; verify release type
Renal measure
Use the renal measure explicitly present in the RX passage.
Source revision
Mirror revision not established in the reviewed passage.
Retrieved
2026-11-07 (not the revision date)

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

This mirror and the underlying product label share a source family.

RX List: selected renal passage

The mirror specifically restricts controlled-release disopyramide in severe renal insufficiency.

Source revision: Mirror revision not established in the reviewed passage. | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/norpace-drug/

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Norpace / Norpace CR - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 22, posted Aug 25, 2026

Renal measure: Creatinine clearance (CrCl), mL/min

Read this dated source finding
Rxlist

Norpace / Norpace CR - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Norpace / Norpace CR - labeled renal guidance

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Disopyramide phosphate (Norpace / Norpace CR), oral capsules; verify release type

Renal method: Creatinine clearance (CrCl), mL/min
Retrieved: 2026-11-07

GlobalRPh RX List

Norpace / Norpace CR - selected RX renal passage

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Disopyramide phosphate (Norpace / Norpace CR), oral capsules; verify release type

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Norpace / Norpace CR - product and source limitations

Confirm the release formulation before selecting an interval and monitor conduction and anticholinergic toxicity.

How to use this: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The original page lists controlled-release usual doses but does not explicitly identify a controlled-release renal algorithm. Do not transfer immediate-release interval recommendations to controlled-release products.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/disopyramide/

Usual Dosing (Adults)

Weight <50 kg: 100 mg every 6 hours or controlled-release 200 mg every 12 hours. Weight >50 kg: 150 mg every 6 hours or controlled-release 300 mg every 12 hours. With no response, may increase to 200 mg every 6 hours. The source maximum required for severe refractory ventricular tachycardia is 400 mg every 6 hours.

GRPH-disopyramide-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

CrCl >40 mL/min: no change; 30 to 40: 100 mg every 8 hours; 15 to 30: 100 mg every 12 hours; <15: 100 mg every 24 hours.

Alternative source strategy: CrCl 30 to 40, reduce dose 50%; CrCl 15 to 30, reduce dose 75%.

GRPH-disopyramide-02 · Source section: Renal DosingRenal section finder

Hemodialysis

100 mg every 24 hours. Not dialyzable.

GRPH-disopyramide-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Norpace / Norpace CR - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Disopyramide phosphate (Norpace / Norpace CR), oral capsules; verify release type

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 22, posted Aug 25, 2026
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: Renal Impairment

Avoid the controlled-release Norpace CR formulation at CrCl 40 mL/min or less. Immediate-release disopyramide has separate clearance-based intervals. Confirm the release formulation before selecting an interval and monitor conduction and anticholinergic toxicity.

RDM74-norpace-official-1 · Source locator: Renal guidance: Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2aa1642-d262-4520-bc6a-9fd3ad795677
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 22, posted Aug 25, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
c63cfac7a871a9f71905c8a3a1e00c46125cedf602dbfd1465ae1e5d8109a376
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Norpace / Norpace CR - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Disopyramide phosphate (Norpace / Norpace CR), oral capsules; verify release type

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror specifically restricts controlled-release disopyramide in severe renal insufficiency.

RDM74-norpace-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/norpace-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
22fb9b9ad49481e8f2f21166bd68cf78f71483e1023583f4df015afc6c1f6b89

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/disopyramide/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
ae985c3c23447fb5f0f04a56590609f26307bf3ce285943067a37b5bd8f8d8f4
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top